Last reviewed · How we verify
Omaveloxolone Lotion 0.5%
Omaveloxolone Lotion 0.5% is a Small molecule drug developed by Biogen. It is currently in Phase 2 development. Also known as: RTA 408 Lotion 0.5%.
At a glance
| Generic name | Omaveloxolone Lotion 0.5% |
|---|---|
| Also known as | RTA 408 Lotion 0.5% |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE (PHASE2)
- RTA 408 Lotion in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omaveloxolone Lotion 0.5% CI brief — competitive landscape report
- Omaveloxolone Lotion 0.5% updates RSS · CI watch RSS
- Biogen portfolio CI
Frequently asked questions about Omaveloxolone Lotion 0.5%
What is Omaveloxolone Lotion 0.5%?
Omaveloxolone Lotion 0.5% is a Small molecule drug developed by Biogen.
Who makes Omaveloxolone Lotion 0.5%?
Omaveloxolone Lotion 0.5% is developed by Biogen (see full Biogen pipeline at /company/biogen).
Is Omaveloxolone Lotion 0.5% also known as anything else?
Omaveloxolone Lotion 0.5% is also known as RTA 408 Lotion 0.5%.
What development phase is Omaveloxolone Lotion 0.5% in?
Omaveloxolone Lotion 0.5% is in Phase 2.
Related
- Manufacturer: Biogen — full pipeline
- Also known as: RTA 408 Lotion 0.5%
- Compare: Omaveloxolone Lotion 0.5% vs similar drugs
- Pricing: Omaveloxolone Lotion 0.5% cost, discount & access